The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | IDH inhibition in AML therapy
The last 5-10 years has been a very exciting time for the treatment of myeloid malignancies, with great advances in targeted therapies. Amir Fathi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses therapy targeting isocitrate dehydrogenase (IDH) in acute myeloid leukaemia (AML). Dr Fathi highlights studies which hare evaluating IDH inhibitors as a monotherapy or in combination with other types of treatment, for which the preliminary data is promising. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
